Symbols / KOD Stock $45.43 +2.99% Kodiak Sciences Inc.

Healthcare • Biotechnology • United States • NGM
KOD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Victor Perlroth M.D.
Exch · Country NGM · United States
Market Cap 2.82B
Enterprise Value 2.65B
Income -229.97M
Sales —
FCF (ttm) -44.38M
Book/sh 2.55
Cash/sh 3.40
Employees 124
Insider 10d —
IPO Oct 04, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -13.30
PEG —
P/S —
P/B 17.79
P/C —
EV/EBITDA -12.28
EV/Sales —
Quick Ratio 4.61
Current Ratio 4.72
Debt/Eq 37.60
LT Debt/Eq —
EPS (ttm) -4.32
EPS next Y -3.42
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-31
ROA -42.64%
ROE -149.49%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 62.16M
Shs Float 38.56M
Insider Own 5.22%
Instit Own 90.05%
Short Float 26.45%
Short Ratio 5.41
Short Interest 10.32M
52W High 47.84
vs 52W High -5.04%
52W Low 2.81
vs 52W Low 1,516.73%
Beta 2.40
Impl. Vol. 0.78%
Rel Volume 0.39
Avg Volume 1.09M
Volume 424.13K
Target (mean) $56.33
Tgt Median $59.00
Tgt Low $14.00
Tgt High $80.00
# Analysts 6
Recom None
Prev Close $44.11
Price $45.43
Change 2.99%
About

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$56.33
Mean price target
2. Current target
$45.43
Latest analyst target
3. DCF / Fair value
$-12.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$45.43
Low
$14.00
High
$80.00
Mean
$56.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-27 main UBS Buy → Buy $80
2026-03-27 reit HC Wainwright & Co. Buy → Buy $58
2026-02-10 reit HC Wainwright & Co. Buy → Buy $38
2026-01-22 main HC Wainwright & Co. Buy → Buy $38
2026-01-07 init UBS — → Buy $50
2025-11-17 main Chardan Capital Neutral → Neutral $14
2025-11-17 main HC Wainwright & Co. Buy → Buy $26
2025-11-11 up HC Wainwright & Co. Neutral → Buy $24
2025-10-24 up JP Morgan Neutral → Overweight $24
2025-10-23 init LifeSci Capital — → Outperform $40
2025-10-06 main Chardan Capital Neutral → Neutral $14
2025-09-25 up Barclays Underweight → Equal-Weight $17
2025-09-22 init Jefferies — → Buy $15
2025-08-18 main HC Wainwright & Co. Neutral → Neutral $5
2025-08-14 main Barclays Underweight → Underweight $7
2025-08-14 up JP Morgan Underweight → Neutral $15
2025-03-31 reit HC Wainwright & Co. Neutral → Neutral $3
2024-12-09 up Jefferies Hold → Buy $20
2024-11-15 main Barclays Underweight → Underweight $4
2024-11-15 reit HC Wainwright & Co. Neutral → Neutral $3
News
RSS: Latest KOD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 BORGESON JOHN A Chief Financial Officer — 28,614 $1.04 $29,759
2026-04-02 BORGESON JOHN A Chief Financial Officer — 30,000 $39.14 $1,197,488
2026-04-02 BORGESON JOHN A Chief Financial Officer — 30,000 $1.04 $31,200
2026-03-25 PERLROTH VICTOR D Chief Executive Officer — 300,000 $1.04 $312,000
2025-12-26 PERLROTH VICTOR D Chief Executive Officer — 12,500 $0.00 $0
2025-12-18 BAKER BROS ADVISORS L.P. Beneficial Owner of more than 10% of a Class of Security — 2,608,696 $23.00 $60,000,008
2025-06-17 BORGESON JOHN A Chief Financial Officer — 723 $3.65 $2,640
2025-06-13 BORGESON JOHN A Chief Financial Officer — 1,875 — —
2024-06-17 BORGESON JOHN A Chief Financial Officer — 2,874 $2.75 $7,904
2024-06-14 BORGESON JOHN A Chief Financial Officer — 5,494 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
234.39
+25.44%
186.85
-32.62%
277.32
-18.76%
341.38
Research And Development
182.37
+44.63%
126.09
-38.88%
206.30
-22.91%
267.59
Selling General And Administration
52.02
-14.38%
60.75
-14.46%
71.02
-3.75%
73.79
General And Administrative Expense
52.02
-14.38%
60.75
-14.46%
71.02
-3.75%
73.79
Other Gand A
52.02
-14.38%
60.75
-14.46%
71.02
-3.75%
73.79
Total Expenses
234.39
+25.44%
186.85
-32.62%
277.32
-18.76%
341.38
Operating Income
-234.39
-25.44%
-186.85
+32.62%
-277.32
+18.76%
-341.38
Total Operating Income As Reported
-234.39
-25.44%
-186.85
+32.62%
-277.32
+18.76%
-341.38
EBITDA
-203.65
-36.22%
-149.50
+36.26%
-234.53
+27.35%
-322.80
Normalized EBITDA
-203.65
-36.22%
-149.50
+36.26%
-234.53
+27.35%
-322.80
Reconciled Depreciation
26.32
-1.45%
26.71
+2.93%
25.95
+135.86%
11.00
EBIT
-229.97
-30.51%
-176.21
+32.35%
-260.48
+21.97%
-333.81
Net Income
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Pretax Income
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Net Non Operating Interest Income Expense
4.52
-59.48%
11.15
-33.33%
16.72
+137.06%
7.05
Interest Expense Non Operating
0.00
0.00
-100.00%
0.01
-27.78%
0.02
Net Interest Income
4.52
-59.48%
11.15
-33.33%
16.72
+137.06%
7.05
Interest Expense
0.00
0.00
-100.00%
0.01
-27.78%
0.02
Interest Income Non Operating
4.52
-59.48%
11.15
-33.38%
16.73
+136.64%
7.07
Interest Income
4.52
-59.48%
11.15
-33.38%
16.73
+136.64%
7.07
Other Income Expense
-0.10
+81.03%
-0.51
-560.00%
0.11
-78.13%
0.50
Other Non Operating Income Expenses
-0.10
+81.03%
-0.51
-560.00%
0.11
-78.13%
0.50
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Net Income From Continuing Operation Net Minority Interest
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Net Income From Continuing And Discontinued Operation
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Net Income Continuous Operations
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Normalized Income
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Net Income Common Stockholders
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Diluted EPS
-4.32
-28.96%
-3.35
+32.60%
-4.97
+22.22%
-6.39
Basic EPS
-4.32
-28.96%
-3.35
+32.60%
-4.97
+22.22%
-6.39
Basic Average Shares
53.21
+1.19%
52.58
+0.32%
52.41
+0.32%
52.25
Diluted Average Shares
53.21
+1.19%
52.58
+0.32%
52.41
+0.32%
52.25
Diluted NI Availto Com Stockholders
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
351.53
+4.75%
335.58
-30.00%
479.37
-28.09%
666.63
Current Assets
214.82
+24.94%
171.94
-40.57%
289.31
-40.47%
486.00
Cash Cash Equivalents And Short Term Investments
209.86
+24.86%
168.07
-41.13%
285.51
-40.39%
478.93
Cash And Cash Equivalents
209.86
+24.86%
168.07
-41.13%
285.51
+49.93%
190.43
Cash Equivalents
207.59
+24.70%
166.46
—
—
Cash Financial
2.28
+41.43%
1.61
—
—
Other Short Term Investments
—
—
0.00
-100.00%
288.50
Prepaid Assets
—
—
—
—
Other Current Assets
4.95
+28.28%
3.86
+1.58%
3.80
-46.24%
7.07
Total Non Current Assets
136.72
-16.45%
163.64
-13.90%
190.06
+5.23%
180.62
Net PPE
121.86
-18.06%
148.73
-15.02%
175.02
+51.20%
115.75
Gross PPE
181.34
-4.56%
189.99
-3.84%
197.57
+61.32%
122.48
Accumulated Depreciation
-59.47
-44.13%
-41.26
-82.96%
-22.55
-235.40%
-6.72
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
43.06
+0.73%
42.75
+1.46%
42.13
+178.89%
15.11
Construction In Progress
5.16
+22.67%
4.20
-3.82%
4.37
-3.28%
4.52
Other Properties
36.61
-21.29%
46.51
-14.73%
54.54
-8.13%
59.37
Leases
96.51
-0.02%
96.53
+0.00%
96.53
+122.00%
43.48
Other Non Current Assets
14.85
-0.40%
14.91
-0.85%
15.04
-76.82%
64.87
Total Liabilities Net Minority Interest
194.15
+4.78%
185.29
-13.25%
213.59
-7.32%
230.46
Current Liabilities
45.53
+78.05%
25.57
-38.72%
41.73
-20.51%
52.50
Payables And Accrued Expenses
33.47
+123.95%
14.95
-53.24%
31.96
-24.93%
42.57
Payables
12.86
+228.56%
3.92
-71.23%
13.61
+49.05%
9.13
Accounts Payable
12.86
+228.56%
3.92
-71.23%
13.61
+49.05%
9.13
Current Accrued Expenses
20.61
+86.83%
11.03
-39.89%
18.35
-45.12%
33.44
Current Debt And Capital Lease Obligation
12.06
+13.50%
10.63
+8.78%
9.77
-1.57%
9.93
Current Capital Lease Obligation
12.06
+13.50%
10.63
+8.78%
9.77
-1.57%
9.93
Other Current Liabilities
—
—
—
-0.00
Total Non Current Liabilities Net Minority Interest
148.62
-6.95%
159.72
-7.07%
171.86
-3.43%
177.97
Long Term Debt And Capital Lease Obligation
47.12
-21.10%
59.72
-16.90%
71.86
-7.64%
77.81
Long Term Capital Lease Obligation
47.12
-21.10%
59.72
-16.90%
71.86
-7.64%
77.81
Tradeand Other Payables Non Current
—
—
—
0.00
Other Non Current Liabilities
101.50
+1.50%
100.00
+0.00%
100.00
-0.16%
100.16
Stockholders Equity
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Common Stock Equity
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Capital Stock
0.01
+20.00%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+20.00%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
61.76
+17.13%
52.73
+0.42%
52.51
+0.33%
52.33
Ordinary Shares Number
61.76
+17.13%
52.73
+0.42%
52.51
+0.33%
52.33
Additional Paid In Capital
1,716.08
+16.03%
1,479.02
+4.28%
1,418.31
+6.68%
1,329.51
Retained Earnings
-1,558.70
-17.31%
-1,328.74
-15.29%
-1,152.53
-29.20%
-892.04
Gains Losses Not Affecting Retained Earnings
—
—
0.00
+100.00%
-1.31
Other Equity Adjustments
—
—
—
-1.31
Total Equity Gross Minority Interest
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Total Capitalization
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Working Capital
169.28
+15.66%
146.36
-40.88%
247.58
-42.89%
433.51
Invested Capital
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Total Debt
59.18
-15.87%
70.34
-13.83%
81.63
-6.95%
87.73
Capital Lease Obligations
59.18
-15.87%
70.34
-13.83%
81.63
-6.95%
87.73
Net Tangible Assets
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Tangible Book Value
157.38
+4.72%
150.29
-43.45%
265.78
-39.06%
436.17
Dueto Related Parties Non Current
—
—
—
100.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-136.01
-15.93%
-117.32
+23.91%
-154.18
+25.32%
-206.46
Cash Flow From Continuing Operating Activities
-136.01
-15.93%
-117.32
+23.91%
-154.18
+25.32%
-206.46
Net Income From Continuing Operations
-229.97
-30.51%
-176.21
+32.36%
-260.49
+21.97%
-333.82
Depreciation Amortization Depletion
26.32
-1.45%
26.71
+2.93%
25.95
+135.86%
11.00
Depreciation
26.32
-1.45%
26.71
+2.93%
25.95
+135.86%
11.00
Depreciation And Amortization
26.32
-1.45%
26.71
+2.93%
25.95
+135.86%
11.00
Other Non Cash Items
0.02
-94.37%
0.35
+142.26%
-0.84
-49.20%
-0.56
Stock Based Compensation
58.86
-2.24%
60.21
-32.01%
88.56
-16.48%
106.03
Asset Impairment Charge
1.91
0.00
0.00
—
Operating Gains Losses
—
—
0.00
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.00
0.00
Change In Working Capital
6.85
+124.12%
-28.39
-285.94%
-7.36
-161.49%
11.96
Change In Prepaid Assets
0.61
+1115.00%
-0.06
-100.71%
8.45
+407.98%
-2.74
Change In Payables And Accrued Expense
17.34
+201.64%
-17.06
-133.43%
-7.31
-1147.44%
-0.59
Change In Accrued Expense
9.27
+225.80%
-7.37
+42.89%
-12.91
-474.67%
-2.25
Change In Payable
8.07
+183.26%
-9.69
-273.18%
5.60
+237.17%
1.66
Change In Account Payable
8.07
+183.26%
-9.69
-273.18%
5.60
+237.17%
1.66
Change In Other Current Assets
0.06
+591.67%
-0.01
-102.82%
0.43
-94.23%
7.38
Change In Other Current Liabilities
-11.16
+0.76%
-11.25
-26.09%
-8.92
-212.84%
7.91
Investing Cash Flow
-0.51
+32.98%
-0.76
-100.30%
249.23
+174.06%
-336.51
Cash Flow From Continuing Investing Activities
-0.51
+32.98%
-0.76
-100.30%
249.23
+174.06%
-336.51
Net PPE Purchase And Sale
-0.51
-26.50%
-0.40
+99.03%
-41.43
+12.53%
-47.36
Purchase Of PPE
-0.51
-26.50%
-0.40
+99.03%
-41.43
+12.53%
-47.36
Capital Expenditure
-0.51
-26.50%
-0.40
+99.03%
-41.43
+12.53%
-47.36
Net Investment Purchase And Sale
0.00
+100.00%
-0.35
-100.12%
290.65
+200.52%
-289.15
Purchase Of Investment
0.00
+100.00%
-0.35
+99.28%
-49.35
+88.46%
-427.77
Sale Of Investment
0.00
0.00
-100.00%
340.00
+145.28%
138.62
Financing Cash Flow
178.30
+35489.22%
0.50
+1516.13%
0.03
-98.36%
1.90
Cash Flow From Continuing Financing Activities
178.30
+35489.22%
0.50
+1516.13%
0.03
-98.36%
1.90
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
172.96
0.00
0.00
0.00
Common Stock Payments
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
0.00
Proceeds From Stock Option Exercised
5.34
+966.27%
0.50
+107.02%
0.24
-87.55%
1.94
Net Other Financing Charges
—
—
-0.21
-330.61%
-0.05
Changes In Cash
41.79
+135.54%
-117.57
-223.66%
95.07
+117.57%
-541.08
Beginning Cash Position
174.26
-40.29%
291.83
+48.32%
196.76
-73.33%
737.83
End Cash Position
216.05
+23.98%
174.26
-40.29%
291.83
+48.32%
196.76
Free Cash Flow
-136.51
-15.97%
-117.72
+39.82%
-195.61
+22.93%
-253.82
Interest Paid Supplemental Data
0.00
0.00
-100.00%
0.01
-27.78%
0.02
Amortization Of Securities
—
0.00
+100.00%
-0.85
+20.79%
-1.07
Common Stock Issuance
172.96
0.00
0.00
0.00
Issuance Of Capital Stock
172.96
0.00
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category